BackArtiva Biotherapeutics Overview

Artiva Biotherapeutics Current Cash

Track Artiva Biotherapeutics's current cash ($300M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$301.45M
↑ 958.92% YoYΔ $272.99M vs prior year quarter

Peer trimmed avg / median

Loading

Artiva Biotherapeutics Current Cash History

Loading

Artiva Biotherapeutics vs. peers: Current Cash Comparison

Loading

Artiva Biotherapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Artiva Biotherapeutics (ARTV) FAQ

Artiva Biotherapeutics (ARTV) currently reports a current cash of $300M as of June 2026. That compares with $28M in the prior-year period — up 958.9% year over year. Use the charts on this page to explore Artiva Biotherapeutics's current cash history and peer comparisons.

Artiva Biotherapeutics's current cash increased from $28M to $300M — a 958.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Artiva Biotherapeutics reported $300M in current cash as of June 2026. That compares with $28M in the prior-year period — up 958.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $300M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Artiva Biotherapeutics, and consider following ARTV for alerts when major investors trade the stock.